At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AEMD Aethlon Medical
Trading 11-22 12:36:46 EST
0.3963
+0.0109
+2.83%
High0.4049Low0.3770Vol102.32K
Open0.3854D1 Closing0.3854Amplitude7.24%
Mkt Cap5.52MTradable Cap5.48MTotal Shares13.94M
T/O39.77KT/O Rate0.74%Tradable Shares13.84M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Maxim Group Sticks to Their Hold Rating for Aethlon Medical (AEMD)
TIPRANKS  ·  11-15
Maxim Group Sticks to Their Hold Rating for Aethlon Medical (AEMD)
Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-15
Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Aethlon’s Future at Risk: Financial Struggles, Stockholder Dilution, and Market Challenges Loom
TIPRANKS  ·  11-15
Aethlon’s Future at Risk: Financial Struggles, Stockholder Dilution, and Market Challenges Loom
AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures
Zacks Small Cap Research  ·  11-14
AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally
Newsfile  ·  11-14
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally
Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...
GuruFocus.com  ·  11-14
Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...
Aethlon Medical Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-14
Aethlon Medical Inc reports results for the quarter ended September 30 - Earnings Summary
Aethlon Medical Advances Oncology Trials and Global Expansion
TIPRANKS  ·  11-14
Aethlon Medical Advances Oncology Trials and Global Expansion
Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline
Benzinga  ·  11-14
Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
THOMSON REUTERS  ·  11-14
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
PR Newswire  ·  11-14
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
Innovative Medical Technology Advances with First Patient Enrollments
Newsfile  ·  11-12
Innovative Medical Technology Advances with First Patient Enrollments
Aethlon Medical Inc expected to post a loss of 19 cents a share - Earnings Preview
Reuters  ·  11-12
Aethlon Medical Inc expected to post a loss of 19 cents a share - Earnings Preview
Aethlon Medical Enrolls First Patient in Hemopurifier Trial -- Shares Up 14% Pre-Bell
MT Newswires Live  ·  11-11
Aethlon Medical Enrolls First Patient in Hemopurifier Trial -- Shares Up 14% Pre-Bell
BRIEF-Aethlon Medical Reaches Key Milestone With Enrollment Of The First Patient In (FPI) Its Hemopurifier Cancer Trial In Australia
Reuters  ·  11-11
BRIEF-Aethlon Medical Reaches Key Milestone With Enrollment Of The First Patient In (FPI) Its Hemopurifier Cancer Trial In Australia
Aethlon Medical Reaches Key Milestone With Enrollment of the First Patient in (Fpi) Its Hemopurifier® Cancer Trial in Australia
THOMSON REUTERS  ·  11-11
Aethlon Medical Reaches Key Milestone With Enrollment of the First Patient in (Fpi) Its Hemopurifier® Cancer Trial in Australia
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
PR Newswire  ·  11-11
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
PR Newswire  ·  11-06
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
GlobeNewswire  ·  10-29
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR
Zacks Small Cap Research  ·  10-25
OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR

Introduction

Company Name.
Aethlon Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Issue price:
--